Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Choosing between index funds and ETFs depends on trading needs, costs, and tax considerations. This guide outlines practical decision factors for you.
14,885 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Bitcoin surged roughly 7% in a single session, reviving optimism after a choppy stretch. This article breaks down the...
A federal judge blocked the Trump administration from labeling Anthropic a supply chain risk, calling the move a poss...
A retired couple aims to fund $14,500 in monthly expenses from a $2.5 million portfolio. The plan combines three inco...
As AI demand climbs, power reliability becomes the bottleneck. This energy stock helping power AI offers a way to inv...
Regencell Bioscience sits in the high-risk, high-reward world of early-stage biotech. Before you consider investing, ...
IonQ is moving from early-stage hardware to recurring cloud access and software tools. This article breaks down what ...
Bitwise CIO Matt Hougan frames crypto as a contrarian bet for institutional buyers, a view that comes as AI stocks su...
Could oil trend toward $60 a barrel by 2027? This article analyzes the scenario, the forces at play, and concrete sto...
Tragedy tests more than emotions — it tests finances too. This article crafts a practical plan to build resilience af...
A major auto parts distributor faced a sharp stock pullback while earnings declined. This guide breaks down what that...
Fairholme trimmed its stake in The St. Joe Company, but that doesn’t mean the stock isn’t worth a closer look. Here’s...